Eric L Simpson, Melinda Gooderham, Andreas Wollenberg, Stephan Weidinger, April Armstrong, Jennifer Soung, Silvia Ferrucci, Renata Gontijo Lima, Michael M Witte, Wen Xu, Hany ElMaraghy, Chitra R Natalie, Evangeline Pierce, Andrew Blauvelt
IMPORTANCE: Lebrikizumab (LEB), a high-affinity monoclonal antibody targeting interleukin (IL)-13, demonstrated efficacy and safety in patients with moderate-to-severe atopic dermatitis (AD) during 16 weeks of monotherapy in a phase 2b trial, and two 52-week phase 3 trials. OBJECTIVE: To evaluate efficacy and safety of LEB combined with low- to mid-potency topical corticosteroids (TCS) in patients with moderate-to-severe AD. DESIGN, SETTING, AND PARTICIPANTS: The ADhere trial was a 16-week randomized, double-blinded, placebo (PBO)-controlled, multicenter, phase 3 clinical trial conducted from February 3, 2020, to September 16, 2021...
January 11, 2023: JAMA Dermatology